# Alnylam Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 31.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/alnylam-pharmaceuticals-inc.consensus-buy-rating-and-31.8-upside-potential/4121132985
- Published: 2023-11-16T13:37:03+00:00
- Author: Charlotte Edwards

**Alnylam Pharmaceuticals, Inc.** with ticker code (ALNY) now have 23 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between $395.00 and $135.00 suggesting an average Analsyt 
target price of $224.09. Given that the stocks previous close was at $169.99 this
would imply there is now a potential upside of 31.8%. It’s also worth noting that
there is a 50 day moving average of $172.30 and the 200 day MA is $191.24. The market
capitalization for the company is 21.47B. The current share price for the company
is: $171.05 USD

 The potential market cap would be $28,297,083,686 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $13.86 and
a -6.01% return on assets.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The
Company is engaged in developing therapeutics based on ribonucleic acid interference(
RNAi). Its pipeline includes five marketed products and over ten clinical programs,
including several in late-stage development, across four strategic therapeutic areas(
STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases,
and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), 
AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran).
ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin
amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase
1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease
manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting
hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.

Share on: